AARD trades 106.8% below Wall Street's consensus target of $3.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes AARD achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 24, 2026, Aardvark Therapeutics, Inc. Common Stock (AARD) has a Wall Street consensus price target of $3.00, based on estimates from 9 covering analysts. With the stock currently trading at $1.39, this represents a potential upside of +106.8%. The company has a market capitalization of $30M.
Analyst price targets range from a low of $3.00 to a high of $3.00, representing a 0% spread in expectations. The median target of $3.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, AARD trades at a trailing P/E of -0.5x. Analysts expect EPS to grow +1.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RYTMRhythm Pharmaceuticals, Inc. | $6.1B | $89.27 | $144.43 | +61.8% | Buy | — | 22 |
 VNDAVanda Pharmaceuticals Inc. | $241M | $4.01 | $15.50 | +286.5% | Buy | — | 19 |
 IMVTImmunovant, Inc. | $5.9B | $28.41 | $40.00 | +40.8% | Buy | — | 23 |
 CGEMCullinan Therapeutics, Inc. | $883M | $14.37 | $34.75 | +141.8% | Buy | — | 8 |
 NUVLNuvalent, Inc. | $9.1B | $123.96 | $127.32 | +2.7% | Hold | — | 19 |
 VKTXViking Therapeutics, Inc. | $2.8B | $24.40 | $97.80 | +300.8% | Buy | — | 24 |
 GPCRStructure Therapeutics Inc. | $1.2B | $21.19 | $90.50 | +327.1% | Buy | — | 14 |
 TERNTerns Pharmaceuticals, Inc. | $4.8B | $52.95 | $51.40 | -2.9% | Buy | — | 16 |
 ELVNEnliven Therapeutics, Inc. | $3.0B | $41.52 | $76.29 | +83.7% | Buy | — | 9 |
 KYMRKymera Therapeutics, Inc. | $9.1B | $110.76 | $138.20 | +24.8% | Buy | — | 27 |
Quick answers to the most common questions about buying AARD stock.
The consensus Wall Street price target for AARD is $3, representing 106.8% upside from the current price of $1.39. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
AARD has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is mixed, with 4 Hold ratings making up the largest segment. The consensus 12-month price target of $3 implies 106.8% upside from current levels.
AARD's current price is $1.39 with a consensus target of $3 (106.8% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $3 for AARD, while the most conservative target is $3. The consensus of $3 represents the median expectation. These targets typically reflect 12-month expectations.
AARD is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 4 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month AARD stock forecast based on 9 Wall Street analysts shows a consensus price target of $3, with estimates ranging from $3 (bear case) to $3 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on AARD, with a "Buy" consensus rating and $3 price target (106.8% upside). 4 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
AARD analyst price targets range from $3 to $3, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $3 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.